Macular disease
Melbourne study to put new AMD tools under microscope
The University of Melbourne is recruiting optometrists to test new clinical tools, as well as an auditing system, it has...
Read moreDetails
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the...
Read moreDetails
Perth partnership targets childhood blindness and $1 billion market
The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of...
Read moreDetails
Latest eye injection proposals draw sharp rebuke from ophthalmology
Controversial plans to dramatically reduce the rebate for intravitreal injections and also allow non-ophthalmologists to perform the procedure have divided...
Read moreDetails
Investors take note of Opthea’s potential
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate...
Read moreDetailsNew Australian study results add to Ozurdex?s efficacy
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has...
Read moreDetails
Shares soar as Australian AMD drug outperforms Lucentis
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis...
Read moreDetails